Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded access study data suggesting the investigational therapy may deliver clinically meaningful benefits for patients. Speaking with Proactive, CEO Ivor Elrifi said the placebo-controlled study has fully enrolled 48 participants across several leading US institutions, including Harvard, Yale, Cornell, Johns Hopkins, UMass Buffalo and Thomas Jefferson.
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS), marking a key milestone for the company's lead drug candidate. The randomized, double-blind, placebo-controlled study, known as INFORM-MS (NCT06292923), is assessing the safety and potential efficacy of intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate immune activity and reduce neuroinflammation.
Tiziana Life Sciences price target boosted on foralumab update
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data for its lead drug candidate, foralumab, in multiple neuroinflammatory conditions. In a note to clients, the firm wrote that it is “increasingly confident on the potential success of foralumab in multiple neuroinflammatory conditions.
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well tolerated over extended treatment in patients with non-active secondary progressive multiple sclerosis (na-SPMS), with encouraging signs of disability stabilization and reduced fatigue. The biotechnology company said data collected through March 2026, updated from an earlier March 2025 readout, covered 14 patients enrolled in the ongoing program evaluating foralumab, a fully human anti-CD3 monoclonal antibody administered intranasally.
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2 Multiple System Atrophy trial showing up to 35% and 24% reductions in brain inflammation markers following intranasal foralumab treatment. The reductions were observed in areas including the basal ganglia and cerebellar white matter, regions known to be involved in the neurodegenerative processes underlying MSA, a rare, progressive disorder for which no approved disease-modifying treatments currently exist.
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function linked to Long COVID, according to a study published on bioRxiv. The study evaluated foralumab, a fully human anti-CD3 monoclonal antibody administered through the nose, in a mouse model designed to mimic neurological symptoms of Long COVID without direct viral infection of the brain.
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation associated with aging. The company highlighted that neuro inflammation is widely recognized as a contributing factor to cognitive decline in age-related neurological conditions.
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with neuroprotective changes in patients with a progressive form of multiple sclerosis. The late-breaking findings were presented by investigators from Brigham and Women's Hospital in a poster detailing results in 10 patients with non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse activity (PIRA).
Tiziana Life Sciences publishes positive study on intranasal MS therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive multiple sclerosis (SPMS) has been published in the journal Neurology Neuroimmunology & Neuroinflammation. The study, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” evaluated intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in 10 patients with non-active SPMS (na-SPMS) who continued to progress despite prior B-cell therapies.
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership and existing shareholders, as the biotechnology company moves to advance late-stage clinical development of its lead drug candidate. The company said on Friday after than it has completed its previously disclosed company best efforts registered direct offering of 7,040,000 ordinary shares at a price of $1.25 per share.
Tiziana Life Sciences unveils registered direct offering of up to $17.6M
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately $17.6 million in gross proceeds, including potential proceeds from attached warrants. Tiziana said the proceeds from the offering are expected to fund the completion of its Phase 2 clinical trials for non-active secondary progressive multiple sclerosis and multiple system atrophy, as well as support top-line data readouts from both studies.
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the US Food and Drug Administration (FDA), reporting no drug-related serious adverse events associated with intranasal foralumab after a cumulative exposure of 37.4 patient-years. The DSUR covers the period from September 21, 2024, to September 2, 2025, and summarizes safety and tolerability data for intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed for neuroinflammatory diseases.
